Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Maze Therapeutics, Inc.NASDAQ: MAZE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 97.8%

Gross margin was 97.8% in Q1 FY2026. On a trailing-twelve-month basis it was 92.0%, down 8.0 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
97.8%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
92.0%-8.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2024
100.0%
Year-over-year change
—

Gross Margin vs competitors

How MAZE compares with its peers on the latest reported figures

  • MAZE's LTM Mar 2026 gross margin of 92.0% is the 2nd highest of the 7 companies compared; the peer median is 81.0%.
  • Its year-over-year change of -8.0 pp is the 3rd highest of 7, against a peer median of -17.5 pp.
MAZE Competitors Peer median
Gross Margin for MAZE and competitors
Company Period LTM level YoY 3-year change
BIOABioAge Labs, Inc.LTM Mar 202699.4% -0.6 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
ARDXArdelyx, Inc.LTM Mar 202691.9% +7.7 pp-2.6 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
SEPNSepterna, Inc.LTM Sep 202679.9% -20.1 pp—
TVTXTravere Therapeutics, Inc.LTM Sep 202660.7% -37.0 pp+1.9 pp
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding MAZE) 81.0%-17.5 pp-0.3 pp

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.